GutHeart: Targeting Gut Microbiota to Treat Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT02637167

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02637167
Other papers using this trial's data
  • Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity Genome medicine, 2024-02-08 DOI, PubMed 38331891, PMC10854170 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02637167. Randomized; no masking; primary purpose treatment. Start 2016-03-11 (registry gives no type); primary completion 2019-06-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GutHeart: Targeting Gut Microbiota to Treat Heart Failure
Condition
Systolic Heart Failure
Intervention (Drug)
Rifaximin
Intervention (Drug)
Saccharomyces boulardii
Lead sponsor
Oslo University Hospital (class: other)

Record details

Record id
cardio:ct-nct02637167
Content hash
9b9f0382a4197cd6c7f8ef5e6679df8c6cc16de6a79bad81db89c0df3a9574a6